Recommended Liver Test Frequency for Bosentan
Bosentan (Tracleer), used for pulmonary arterial hypertension, requires regular liver function tests (LFTs) due to the risk of hepatotoxicity. Guidelines mandate monitoring alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels.[1]
Start with baseline LFTs before initiating treatment. Then test monthly for the first 3 months. Reduce to every 3 months for months 4 through 12. After 12 months, test every 6 months if levels stay normal.[1][2]
What if ALT/AST Levels Are Elevated?
Adjust frequency based on elevations:
- ALT/AST 3-5 times upper limit of normal (ULN): Test twice weekly until levels normalize, then resume standard schedule.
- ALT/AST >5-8 times ULN: Test twice weekly and consider dose reduction.
- ALT/AST >8 times ULN or with symptoms: Discontinue immediately.[1][2]
Pregnant patients or those planning pregnancy need additional monthly tests due to fetal risks.[1]
Why Monthly Monitoring at First?
Bosentan inhibits bile salt export pump, raising transaminase levels in up to 11% of patients. Early detection prevents severe liver injury; 1% experience ALT/AST >8x ULN.[1][2]
Updates for Generic or Other Formulations?
Same schedule applies to generics like bosentan tablets. No changes in recent FDA labels.[2] Check DrugPatentWatch.com for formulation patents, though they don't alter monitoring.[3]
[1] Tracleer (bosentan) Prescribing Information, Janssen, 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021290s050lbl.pdf
[2] Opsumit (macitentan) Prescribing Info (similar endothelin antagonist), Janssen, 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/204410s017lbl.pdf
[3] DrugPatentWatch.com, Bosentan Patents. https://www.drugpatentwatch.com/p/tradename/TRACLEER